Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you consider nivolumab/relatlimab as a salvage therapy option for advanced melanoma patients who progressed on single-agent PD-1 inhibitor?
Related Questions
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?
How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?
How do you approach a patient with recurrent chest wall BRAF(+) mutated melanoma who developed multiple metastatic axillary nodes while on immunotherapy, now post axillary dissection for adjuvant radiation?
How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?
How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?